Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)
复制标题
关于肿瘤坏死因子阻断剂治疗类风湿性关节炎和其他风湿性疾病的最新共识声明（2001年4月）
DOI：
--
复制
发表时间：
2001
影响因子：
27.4
通讯作者：
A. Kavanaugh
中科院分区：
文献类型：
--
作者：
D. Furst;E. Keystone;F. Breedveld;J. Kalden;J. Smolen;C. Antoni;G. Burmester;L. Crofford;A. Kavanaugh
TNF阻断剂已被证明是有效的DMARD，并且它们是治疗RA的主要进展。它们的使用正在扩展到其他风湿性疾病。然而，已经发现了罕见和意外的毒性，并且在使用过程中可能会发现其他毒性。需要在选定的有效性，毒性和TNF阻断剂的一般使用领域进行研究，以帮助进一步确定这些药物的最适当用途。使用这些药物将需要有经验的医生在诊断，治疗和评估类风湿关节炎和其他风湿性疾病。这些医生需要对疗效和毒性进行长期观察。当在这种疾病中使用TNF阻断剂时，必须进一步考虑的因素包括成本和亚组数据仍在采集中的认识。我们希望，这一声明，这是基于最好的证据，在其创建时，并修改了专家的意见，将促进这些药物的最佳使用我们的患者与RA和其他风湿性疾病。
TNF blocking agents have proved to be effective DMARDs and they have been a major advance in the treatment of RA. Their use is expanding to other rheumatic diseases. However, rare to uncommon and unexpected toxicities have been found and others may yet be found during their use. Studies in selected areas of efficacy, toxicity, and general use of TNF blocking agents are needed to help further define the most appropriate use of these agents. Use of these drugs will require doctors experienced in the diagnosis, treatment, and assessment of RA and other rheumatic diseases. These doctors will need to make long term observations of efficacy and toxicity. Further considerations which must be made when using TNF blocking agents in this disease include the cost and a recognition that data in subgroups are still being acquired. It is hoped that this statement, which is based upon the best evidence available at the time of its creation, and modified by expert opinion, will facilitate the optimal use of these agents for our patients with RA and other rheumatic diseases.
影响因子：
158.5
作者：
Lovell, DJ;Giannini, EH;Finck, BK
通讯作者：
Finck, BK